Symbols / LXRX
LXRX Chart
About
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company offers Sotagliflozin, an orally-delivered small molecule drug to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease or CKD, and other cardiovascular risk factors. Its orally-delivered small molecule drug candidates under development include sotagliflozin for the treatment of hypertrophic cardiomyopathy or HCM and type 1 diabetes that is in Phase 3 clinical trial; LX9211, which has completed Phase II clinical trials for the treatment of neuropathic pain; and LX9851 for the treatment of obesity and associated cardiometabolic disorders, as well as for weight management. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 622.62M |
| Enterprise Value | 486.83M | Income | -68.58M | Sales | 70.86M |
| Book/sh | 0.33 | Cash/sh | 0.32 | Dividend Yield | — |
| Payout | 0.00% | Employees | 103 | IPO | — |
| P/E | — | Forward P/E | -6.04 | PEG | — |
| P/S | 8.79 | P/B | 4.50 | P/C | — |
| EV/EBITDA | -9.03 | EV/Sales | 6.87 | Quick Ratio | 5.45 |
| Current Ratio | 5.64 | Debt/Eq | 54.05 | LT Debt/Eq | — |
| EPS (ttm) | -0.19 | EPS next Y | -0.25 | EPS Growth | — |
| Revenue Growth | 7.10% | Earnings | 2026-03-05 | ROA | -12.94% |
| ROE | -45.92% | ROIC | — | Gross Margin | -6.98% |
| Oper. Margin | -85.93% | Profit Margin | -96.77% | Shs Outstand | 417.87M |
| Shs Float | 359.56M | Short Float | 18.88% | Short Ratio | 7.58 |
| Short Interest | — | 52W High | 1.83 | 52W Low | 0.28 |
| Beta | 1.00 | Avg Volume | 2.41M | Volume | 638.91K |
| Target Price | $2.92 | Recom | None | Prev Close | $1.48 |
| Price | $1.49 | Change | 0.68% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$2.92
Mean price target
2. Current target
$1.49
Latest analyst target
3. DCF / Fair value
$-1.66
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.49
Low
$1.00
High
$6.00
Mean
$2.92
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-09-02 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
| 2025-08-07 | main | Citigroup | Buy → Buy | $2 |
| 2025-06-24 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
| 2025-03-28 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
| 2025-03-07 | main | Piper Sandler | Overweight → Overweight | $6 |
| 2025-03-07 | reit | Needham | Hold → Hold | — |
| 2025-03-07 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
| 2025-03-04 | down | Leerink Partners | Outperform → Market Perform | $1 |
| 2025-03-03 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
| 2025-03-03 | reit | Needham | Hold → Hold | — |
| 2025-01-29 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
| 2025-01-29 | reit | Needham | Hold → Hold | — |
| 2024-12-23 | reit | Needham | Hold → Hold | — |
| 2024-11-25 | reit | Needham | — → Hold | — |
| 2024-11-22 | reit | Needham | — → Hold | — |
| 2024-11-13 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2024-11-13 | reit | Needham | — → Hold | — |
| 2024-11-05 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2024-11-01 | main | HC Wainwright & Co. | Buy → Buy | $6 |
| 2024-11-01 | reit | Needham | — → Hold | — |
- Insider Purchase: Director at $LXRX Buys 100,000 Shares - Quiver Quantitative Mon, 23 Feb 2026 13
- How The Lexicon Pharmaceuticals (LXRX) Story Is Shifting With Fine Tuned Targets And Trials - Yahoo Finance Mon, 23 Feb 2026 06
- Lexicon Pharma stock spikes after insider buy (LXRX:NASDAQ) - Seeking Alpha hu, 19 Feb 2026 16
- Experimental heart, diabetes and pain drugs move ahead at Lexicon - Stock Titan Mon, 12 Jan 2026 08
- Lexicon Pharmaceuticals director Debbane buys $147,000 in stock By Investing.com - Investing.com UK Wed, 25 Feb 2026 12
- Insider Makes Bold Move With Fresh Lexicon Pharmaceuticals Buy - TipRanks ue, 24 Feb 2026 02
- Citi Raises Lexicon Pharmaceuticals (LXRX) Outlook on Strength of Novo Nordisk Partnership Milestones - Yahoo Finance Fri, 30 Jan 2026 08
- Drug developer Lexicon raises $94.6M to fund pipeline and operations - Stock Titan Fri, 30 Jan 2026 08
- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) stock most popular amongst private equity firms who own 48%, while individual investors hold 27% - Yahoo Finance ue, 23 Dec 2025 08
- Raymond Debbane buys Lexicon Pharmaceuticals (LXRX) shares - Investing.com Nigeria Mon, 23 Feb 2026 13
- Lexicon raises about $94.6M to fund drug work and operations - Stock Titan Fri, 06 Feb 2026 08
- $LXRX stock is up 10% today. Here's what we see in our data. - Quiver Quantitative hu, 19 Feb 2026 19
- Lexicon (Nasdaq: LXRX) to join Jefferies 2025 London Healthcare Conference on Nov. 18 - Stock Titan ue, 11 Nov 2025 08
- Insider Stock Purchases: February 23, 2026 - Quiver Quantitative Mon, 23 Feb 2026 18
- Lexicon (NASDAQ: LXRX) sets Nov. 6 call for third quarter results at 8:30 a.m. ET - Stock Titan hu, 30 Oct 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 150000 | 219755.0 | — | Purchase at price 1.44 - 1.48 per share. | DEBBANE RAYMOND | Director | — | 2026-02-20 00:00:00 | D |
| 1 | 268497 | 352889.0 | — | Purchase at price 1.31 - 1.32 per share. | DEBBANE RAYMOND | Director | — | 2026-02-18 00:00:00 | D |
| 2 | 22400000 | 29120000.0 | — | Stock Award(Grant) at price 1.30 per share. | INVUS GLOBAL MANAGEMENT, LLC | Beneficial Owner of more than 10% of a Class of Security | — | 2026-02-02 00:00:00 | I |
| 3 | 1538462 | 2000001.0 | — | Purchase at price 1.30 per share. | INVUS GLOBAL MANAGEMENT, LLC | Beneficial Owner of more than 10% of a Class of Security | — | 2026-02-02 00:00:00 | I |
| 4 | 36810 | nan | — | — | SOBECKI CHRISTOPHER J | Director | — | 2025-05-13 00:00:00 | D |
| 5 | 36810 | nan | — | — | DEBBANE RAYMOND | Director | — | 2025-05-13 00:00:00 | D |
| 6 | 36810 | nan | — | — | BARKER SAMUEL L | Director | — | 2025-05-13 00:00:00 | D |
| 7 | 36810 | nan | — | — | AMOUYAL PHILIPPE | Director | — | 2025-05-13 00:00:00 | D |
| 8 | 36810 | nan | — | — | SWAIN JUDITH L | Director | — | 2025-05-13 00:00:00 | D |
| 9 | 36810 | nan | — | — | SULLIVAN DIANE E | Director | — | 2025-05-13 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -184.29M | -163.46M | -98.74M | -86.66M |
| TotalUnusualItems | 0.00 | 0.00 | ||
| TotalUnusualItemsExcludingGoodwill | 0.00 | 0.00 | ||
| NetIncomeFromContinuingOperationNetMinorityInterest | -200.40M | -177.12M | -101.94M | -87.76M |
| ReconciledDepreciation | 534.00K | 554.00K | 427.00K | 292.00K |
| ReconciledCostOfRevenue | 616.00K | 85.00K | 0.00 | 0.00 |
| EBITDA | -184.29M | -163.46M | -98.74M | -86.66M |
| EBIT | -184.82M | -164.02M | -99.16M | -86.96M |
| NetInterestIncome | -3.29M | -5.37M | -1.18M | -668.00K |
| InterestExpense | 15.58M | 13.10M | 2.78M | 802.00K |
| InterestIncome | 12.29M | 7.73M | 1.60M | 134.00K |
| NormalizedIncome | -200.40M | -177.12M | -101.94M | -87.76M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -200.40M | -177.12M | -101.94M | -87.76M |
| TotalExpenses | 228.20M | 172.95M | 100.90M | 87.39M |
| TotalOperatingIncomeAsReported | -197.12M | -171.75M | -100.76M | -87.09M |
| DilutedAverageShares | 320.03M | 221.13M | 165.73M | 145.65M |
| BasicAverageShares | 320.03M | 221.13M | 165.73M | 145.65M |
| DilutedEPS | -0.63 | -0.79 | -0.62 | -0.60 |
| BasicEPS | -0.63 | -0.79 | -0.62 | -0.60 |
| DilutedNIAvailtoComStockholders | -200.40M | -177.12M | -101.94M | -87.76M |
| NetIncomeCommonStockholders | -200.40M | -177.12M | -101.94M | -87.76M |
| NetIncome | -200.40M | -177.12M | -101.94M | -87.76M |
| NetIncomeIncludingNoncontrollingInterests | -200.40M | -177.12M | -101.94M | -87.76M |
| NetIncomeContinuousOperations | -200.40M | -177.12M | -101.94M | -87.76M |
| TaxProvision | 0.00 | |||
| PretaxIncome | -200.40M | -177.12M | -101.94M | -87.76M |
| SpecialIncomeCharges | 0.00 | 0.00 | ||
| GainOnSaleOfBusiness | 0.00 | 0.00 | ||
| ImpairmentOfCapitalAssets | 0.00 | 0.00 | ||
| NetNonOperatingInterestIncomeExpense | -3.29M | -5.37M | -1.18M | -668.00K |
| InterestExpenseNonOperating | 15.58M | 13.10M | 2.78M | 802.00K |
| InterestIncomeNonOperating | 12.29M | 7.73M | 1.60M | 134.00K |
| OperatingIncome | -197.12M | -171.75M | -100.76M | -87.09M |
| OperatingExpense | 227.58M | 172.87M | 100.90M | 87.39M |
| ResearchAndDevelopment | 84.48M | 58.89M | 52.82M | 55.05M |
| SellingGeneralAndAdministration | 143.10M | 113.98M | 48.08M | 32.34M |
| GrossProfit | 30.46M | 1.12M | 139.00K | 298.00K |
| CostOfRevenue | 616.00K | 85.00K | 0.00 | 0.00 |
| TotalRevenue | 31.08M | 1.20M | 139.00K | 298.00K |
| OperatingRevenue | 31.08M | 1.20M | 139.00K | 298.00K |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TreasurySharesNumber | 1.53M | 867.97K | 488.00K | 1.17M |
| OrdinarySharesNumber | 361.49M | 244.92M | 188.73M | 148.92M |
| ShareIssued | 363.02M | 245.79M | 189.21M | 150.08M |
| NetDebt | 33.64M | 77.04M | 2.23M | |
| TotalDebt | 108.40M | 106.06M | 55.29M | 2.28M |
| TangibleBookValue | 101.41M | 48.57M | 72.58M | 69.05M |
| InvestedCapital | 246.25M | 192.62M | 165.70M | 113.59M |
| WorkingCapital | 200.94M | 145.00M | 117.69M | 66.80M |
| NetTangibleAssets | 101.41M | 48.57M | 72.58M | 69.05M |
| CapitalLeaseObligations | 8.10M | 6.56M | 6.71M | 2.28M |
| CommonStockEquity | 145.95M | 93.11M | 117.12M | 113.59M |
| TotalCapitalization | 246.25M | 192.62M | 165.70M | 113.59M |
| TotalEquityGrossMinorityInterest | 145.95M | 93.11M | 117.12M | 113.59M |
| StockholdersEquity | 145.95M | 93.11M | 117.12M | 113.59M |
| GainsLossesNotAffectingRetainedEarnings | 119.00K | 31.00K | -428.00K | -10.00K |
| OtherEquityAdjustments | 119.00K | 31.00K | -428.00K | -10.00K |
| TreasuryStock | 4.62M | 2.88M | 2.06M | 7.52M |
| RetainedEarnings | -1.97B | -1.77B | -1.59B | -1.49B |
| AdditionalPaidInCapital | 2.12B | 1.86B | 1.71B | 1.61B |
| CapitalStock | 363.00K | 245.00K | 189.00K | 150.00K |
| CommonStock | 363.00K | 245.00K | 189.00K | 150.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 152.47M | 136.32M | 77.17M | 23.31M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 107.22M | 104.77M | 54.00M | 1.19M |
| LongTermDebtAndCapitalLeaseObligation | 107.22M | 104.77M | 54.00M | 1.19M |
| LongTermCapitalLeaseObligation | 6.92M | 5.26M | 5.42M | 1.19M |
| LongTermDebt | 100.30M | 99.51M | 48.58M | |
| CurrentLiabilities | 45.25M | 31.55M | 23.17M | 22.12M |
| CurrentDebtAndCapitalLeaseObligation | 1.18M | 1.29M | 1.29M | 1.09M |
| CurrentCapitalLeaseObligation | 1.18M | 1.29M | 1.29M | 1.09M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 14.71M | 9.59M | 7.83M | 5.71M |
| PayablesAndAccruedExpenses | 29.36M | 20.66M | 14.05M | 15.32M |
| CurrentAccruedExpenses | 14.56M | 6.28M | 3.66M | 6.17M |
| Payables | 14.80M | 14.39M | 10.39M | 9.15M |
| AccountsPayable | 14.80M | 14.39M | 10.39M | 9.15M |
| TotalAssets | 298.42M | 229.43M | 194.30M | 136.91M |
| TotalNonCurrentAssets | 52.23M | 52.88M | 53.43M | 47.99M |
| OtherNonCurrentAssets | 368.00K | 828.00K | 412.00K | 2.27M |
| GoodwillAndOtherIntangibleAssets | 44.54M | 44.54M | 44.54M | 44.54M |
| Goodwill | 44.54M | 44.54M | 44.54M | 44.54M |
| NetPPE | 7.32M | 7.51M | 8.48M | 3.44M |
| AccumulatedDepreciation | -2.09M | -4.54M | -3.98M | -4.85M |
| GrossPPE | 9.40M | 12.05M | 12.46M | 8.30M |
| Leases | 2.18M | 2.18M | 2.05M | 1.31M |
| OtherProperties | 6.82M | 2.27M | ||
| MachineryFurnitureEquipment | 2.39M | 4.35M | 4.00M | 4.72M |
| BuildingsAndImprovements | 4.83M | 5.52M | 6.41M | 2.27M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 246.19M | 176.55M | 140.87M | 88.92M |
| OtherCurrentAssets | 4.53M | 5.13M | 2.48M | 2.16M |
| PrepaidAssets | 2.16M | |||
| Inventory | 231.00K | 381.00K | 0.00 | |
| FinishedGoods | 128.00K | 281.00K | 0.00 | |
| WorkInProcess | 0.00 | 100.00K | 0.00 | |
| RawMaterials | 103.00K | 0.00 | 0.00 | |
| Receivables | 3.47M | 1.01M | 28.00K | 14.00K |
| AccountsReceivable | 3.47M | 1.01M | 28.00K | 14.00K |
| CashCashEquivalentsAndShortTermInvestments | 237.96M | 170.03M | 138.36M | 86.74M |
| OtherShortTermInvestments | 171.30M | 147.56M | 92.01M | 22.68M |
| CashAndCashEquivalents | 66.66M | 22.46M | 46.34M | 64.06M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -179.81M | -162.37M | -90.18M | -88.24M |
| RepurchaseOfCapitalStock | -1.73M | -824.00K | -864.00K | -2.67M |
| RepaymentOfDebt | -11.70M | |||
| IssuanceOfDebt | 0.00 | 49.96M | 48.87M | |
| IssuanceOfCapitalStock | 241.32M | 138.82M | 94.20M | 37.08M |
| CapitalExpenditure | -1.03M | -470.00K | -1.33M | -1.22M |
| InterestPaidSupplementalData | 12.92M | 10.06M | 2.29M | 799.00K |
| EndCashPosition | 66.66M | 22.46M | 46.34M | 64.06M |
| BeginningCashPosition | 22.46M | 46.34M | 64.06M | 126.26M |
| ChangesInCash | 44.19M | -23.88M | -17.72M | -62.20M |
| FinancingCashFlow | 238.35M | 187.96M | 142.21M | 22.71M |
| CashFlowFromContinuingFinancingActivities | 238.35M | 187.96M | 142.21M | 22.71M |
| NetOtherFinancingCharges | -1.31M | |||
| ProceedsFromStockOptionExercised | 64.00K | 0.00 | 0.00 | |
| NetPreferredStockIssuance | 241.32M | 0.00 | 0.00 | |
| PreferredStockIssuance | 241.32M | 0.00 | 0.00 | |
| NetCommonStockIssuance | -1.73M | 138.00M | 93.34M | 34.41M |
| CommonStockPayments | -1.73M | -824.00K | -864.00K | -2.67M |
| CommonStockIssuance | 0.00 | 138.82M | 94.20M | 37.08M |
| NetIssuancePaymentsOfDebt | 0.00 | 49.96M | 48.87M | -11.70M |
| NetLongTermDebtIssuance | 0.00 | 49.96M | 48.87M | -11.70M |
| LongTermDebtPayments | -11.70M | |||
| LongTermDebtIssuance | 0.00 | 49.96M | 48.87M | |
| InvestingCashFlow | -15.38M | -49.94M | -71.08M | 2.11M |
| CashFlowFromContinuingInvestingActivities | -15.38M | -49.94M | -71.08M | 2.11M |
| NetInvestmentPurchaseAndSale | -14.35M | -49.47M | -69.75M | 3.33M |
| SaleOfInvestment | 314.40M | 173.87M | 64.20M | 37.59M |
| PurchaseOfInvestment | -328.75M | -223.34M | -133.95M | -34.26M |
| NetBusinessPurchaseAndSale | 0.00 | 0.00 | ||
| SaleOfBusiness | 0.00 | 0.00 | ||
| NetPPEPurchaseAndSale | -1.03M | -470.00K | -1.33M | -1.22M |
| SaleOfPPE | 0.00 | 0.00 | ||
| PurchaseOfPPE | -1.03M | -470.00K | -1.33M | -1.22M |
| OperatingCashFlow | -178.78M | -161.90M | -88.85M | -87.02M |
| CashFlowFromContinuingOperatingActivities | -178.78M | -161.90M | -88.85M | -87.02M |
| ChangeInWorkingCapital | 14.24M | 2.66M | 402.00K | -10.23M |
| ChangeInOtherCurrentAssets | 1.15M | 467.00K | 656.00K | 661.00K |
| ChangeInPayablesAndAccruedExpense | 14.80M | 6.45M | 76.00K | -14.16M |
| ChangeInPayable | 14.80M | 6.45M | 76.00K | -14.16M |
| ChangeInAccountPayable | 14.80M | 6.45M | 76.00K | -14.16M |
| ChangeInPrepaidAssets | 598.00K | -2.90M | -316.00K | 2.88M |
| ChangeInInventory | 150.00K | -381.00K | 0.00 | 0.00 |
| ChangeInReceivables | -2.46M | -982.00K | -14.00K | 381.00K |
| ChangesInAccountReceivables | -2.46M | -982.00K | -14.00K | 381.00K |
| OtherNonCashItems | 2.66M | 3.29M | 741.00K | 54.00K |
| StockBasedCompensation | 13.50M | 14.34M | 11.52M | 10.58M |
| AssetImpairmentCharge | 0.00 | 0.00 | ||
| AmortizationOfSecurities | -9.30M | -5.62M | 0.00 | |
| DeferredTax | 0.00 | |||
| DeferredIncomeTax | 0.00 | |||
| DepreciationAmortizationDepletion | 534.00K | 554.00K | 427.00K | 292.00K |
| DepreciationAndAmortization | 534.00K | 554.00K | 427.00K | 292.00K |
| OperatingGainsLosses | 3.00K | 49.00K | ||
| GainLossOnSaleOfPPE | 0.00 | 0.00 | 3.00K | 49.00K |
| GainLossOnSaleOfBusiness | 0.00 | 0.00 | ||
| NetIncomeFromContinuingOperations | -200.40M | -177.12M | -101.94M | -87.76M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for LXRX
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|